Appili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results

Article content

In connection with the termination of the Arrangement Agreement, Appili has secured 3-month extensions to the amounts due under each of (1) the amended and restated secured loan agreement with Long Zone Holdings Inc. (the “LZH Loan”), and (2) the unsecured promissory notes with Bloom Burton & Co. Inc. (the “Bloom Burton Loan”).  Pursuant to the terms of such extensions, all amounts owing under the LZH Loan and the Bloom Burton Loan, together with all accrued and unpaid interest, will be due on August 31, 2025.

Article content

Annual Financial Results

Article content

The Company prepares its financial statements in accordance with IFRS as issued by the International Accounting Standard Board and Part I of Chartered Professional Accountants of Canada Handbook – Accounting.

Article content

The net loss and comprehensive loss of $2.6 million or $0.02 loss per share for FYE 2025, was $1.2 million lower than the net loss and comprehensive loss of $3.8 million or $0.03 loss per share during the year ended March 31, 2024. This relates mainly to a $4 million increase in government assistance, relating to the USAFA Cooperative Agreement, a $1.4 million increase in other income representing waiver fees from Aditxt, $0.2 million decrease in general and administrative expenses, and $0.2 million decrease in business development expense, offset by a $1.7 million increase in research and development expenses, $1.8 million increase in financing costs and $0.4 million increase in foreign exchange loss.

Article content

Article content

On March 31, 2025, the Company had cash of $1.2 million compared to $0.1 million on March 31, 2024.  The Company has included a going concern note in its financial statements for the FYE 2025. In particular, the Company is dependent in large part on successfully raising additional financing through equity and/or non-dilutive funding. For further details, please refer to the Company’s going concern note in the Company’s management’s discussion and analysis (the “MD&A”) for the FYE 2025.

Article content

As of June 25, 2025, the Company had 121,266,120 issued and outstanding Common Shares, 10,910,281 stock options and 37,139,874 warrants outstanding.

Article content

This press release should be read in conjunction with the Company’s audited annual consolidated financial statements for the FYE 2025, and the related MD&A, copies of which are available under the Company’s profile on SEDAR+ at www.sedarplus.ca.

Article content

About Appili Therapeutics
Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial resistant infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.  

Article content

Article content

Forward looking statements
This news release contains “forward-looking statements”, including with respect to the potential for partnered projects to be developed, the potential that Appili will receive government awards and / or contracts related to its proposal submissions, further anticipated milestones and the timing thereof, the Company’s development plans and timelines with respect to ATI-1501, ATI-1701 and ATI-1801, the timing of any milestone and/or royalty payments in respect of ATI-1501,   and the Company’s expectations with respect to its ability to operate as a going concern and satisfy its ongoing working capital requirements. Wherever possible, words such as “may,” “would,” “could,” “should,” “will,” “anticipate,” “believe,” “plan,” “expect,” “intend,” “estimate,” “potential for” and similar expressions have been used to identify these forward-looking statements. These forward-looking statements reflect the current expectations of the Company’s management for future growth, results of operations, performance and business prospects and opportunities and involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, (i) the risk that the Company may not secure any government funding in respect of any proposal submitted prior to the date hereof, (ii) the risk that the Company may not be able to collect the Termination Fee in full or at all, (iii) risks relating to the ability of the Company to repay the LZH Loan and the Bloom Burton Loan as and when they become due, and (iv) those risks listed in the annual information form of the Company dated June 25, 2025, and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedarplus.ca). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.

Article content

Article content

Article content

Article content

Article content

Article content

Article content

Article content